InSights webcasts: Gene therapy in ophthalmology

To watch the on demand webcast please login or create an account.

Gene Therapy in Ophthalmology is a fast moving and promising field. While offering unhoped perspectives for patients, it also raises unprecedented questions; what can we really expect from these new therapies? Which are the current or future developments to be prepared for? Which are the encountered challenges when bringing these medicines in real world? How will they shape the clinical practice in ophthalmology? Those are the questions to be addressed in this webinar by Prof. Camiel Boon, Prof. Rob Collin and Prof. Bart Leroy.

Speakers

  • Prof. dr. Bart Leroy, associate professor of Ophthalmic Genetics and Visual Electrophysiology, Ghent University
  • Prof. dr. Rob Collin, associate professor at the Department of Human Genetics, Radboud University Medical Center, Nijmegen
  • Prof. dr. Camiel Boon, professor of Ophthalmology, Leiden University

Date

You can watch this webcast anytime you want after you login on this webpage.

Easy registration

Create an account or log in with your existing account on this website.

Accreditation

The webcast is accredited by EACCME (ELM20-A00233) for 1.5 CME-points.

Audience

This webcast is primarily intended for ophthalmologists. Other interested healthcare professionals are welcome to join. The webcast will be held in English.

Free webcast

Participation in this webcast is free of charge.

Questions?

If you have any questions, please send an email to nascholing@springer.com.

 

This webcast is sponsored by

NL2010095104

In the context of GDPR, Springer complies with the laws and regulations as laid down by this law. For this webcast it applies that it concerns a collaboration between Springer and Novartis and that they each determine their own purpose and means in the processing of personal data. Springer and Novartis are therefore separately responsible for processing. The privacy conditions that apply can be found here: Springer Healthcare & Novartis.

To continue reading, please log in

Log in with your BSL Account

Log in

Forgot your password?

No BSL Account yet? Please register

Register

More information on BSL Accounts.